Nykode Therapeutics Reports Final P-II Trial (VB-C-02) Results of VB10.16 + Tecentriq (atezolizumab) for Advanced Cervical Cancer
Shots:
- The P-II trial evaluating VB10.16 + Roche’s Tecentriq in 52 patients with advanced or recurrent, non-resectable HPV16+ cervical cancer at sites in the EU
- The results showed an m-OS of ≥25mos. (not reached) & m-PFS of 6.3mos. in PD-L1+ patients while m-OS for the overall population incl. patients with PD-L1- tumors (16.9mos.), m-PFS (4.1mos.), DoR (17.1mos), ORR & DCR (29% & 75%) in PD-L1+ patients (19% & 60% in the overall population)
- In PD-L1+ patients with one prior line of systemic treatment, ORR & DCR (40% & 80%) with a m-PFS (16.9mos.) & m-OS of ≥25mos. (not reached), was well-tolerated and the safety profile was comparable to checkpoint inhibitor monotx. The company plans to initiate a registrational trial for PD-L1+ patients in the US in Q4’23
Ref: GlobeNewswire | Image: Nykode
Related News:- Nykode Reports Interim Results of VB10.16 in P-II (VB C-02) Trial for the Treatment of Advanced Cervical Cancer
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
